

A multiparameter model for non-invasive detection of hypoglycemia

Ole Elvebakk¹, Christian Tronstad¹, Kåre I. Birkeland^{2,3}, Trond G. Jenssen^{2,3,4}, Marit R. Bjørgaas^{5,6}, Hanne L. Gulseth^{7,8}, Håvard Kalvøy¹, Jan O. Høgetveit^{1,9} and Ørjan G. Martinsen^{9,1}

¹Department of Clinical and Biomedical Engineering, Oslo University Hospital, Oslo, Norway

²Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway

³Institute of Clinical Medicine, University of Oslo and Oslo University Hospital

⁴Metabolic and Renal Research Group, UiT The Arctic University of Norway, Tromsø, Norway

⁵Department of Endocrinology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.

⁶Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU – Norwegian University of Science and Technology, Trondheim, Norway.

⁷Department of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo Norway

⁸Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway

⁹Department of Physics, University of Oslo, Oslo, Norway.

Abstract

Severe hypoglycemia is the most serious acute complication for people with type 1 diabetes (T1D). Approximately 25% of people with T1D have impaired ability to recognize impending hypoglycemia, and nocturnal episodes are feared. We have investigated the use of non-invasive sensors for detection of hypoglycemia based on a mathematical model which combines several sensor measurements to identify physiological responses to hypoglycemia. Data from randomized single-blinded euglycemic and hypoglycemic glucose clamps in 20 participants with type 1 diabetes and impaired awareness of hypoglycemia was used in the analyses. Using a sensor combination of sudomotor activity at three skin sites, ECG-derived heart rate and heart rate corrected QT interval, near-infrared and bioimpedance spectroscopy; physiological responses associated with hypoglycemia could be identified with an F1 score accuracy up to 88%. We present a novel model for identification of non-invasively measurable physiological responses related to hypoglycemia, showing potential for detection of moderate hypoglycemia using a wearable sensor system.

Introduction

Even with adequate monitoring and treatment, people with type 1 diabetes (T1D) have higher morbidity and mortality than the general population (Livingstone *et al.*, 2012; Secrest *et al.*, 2010; Lind *et al.*, 2014). In particular, children with T1D have a markedly increased early mortality associated with hypoglycemia (Gagnum *et al.*, 2015). To avoid severe hypoglycemia, self-monitoring of blood glucose is of utmost importance and finger prick testing or other invasive methods are a prerequisite. The use of continuous glucose monitors (CGMs) is increasing, but they are costly, and worldwide most people with diabetes still rely on pin prick testing. The most dangerous situation for a person with T1D is low blood glucose (BG), and the ability to detect hypoglycemia can be impaired during sleep or other situations with altered consciousness (Secrest *et al.*, 2011; Anderbro *et al.*, 2010). Over time, people with T1D may develop impaired awareness of hypoglycemia (IAH), implying adaptation to repeated hypoglycemic episodes and loss of the ability to sense low BG (Graveling and Frier, 2010). The prevalence of IAH among people with T1D is reported to be 20-25%, and the prevalence increases with time since diagnosis (Geddes *et al.*, 2008; Graveling *et al.*, 2014; Olsen *et al.* 2014). The use of CGMs has demonstrated that hypoglycemic events in people with IAH are more frequent than previously known (Agesen *et al.*, 2018), emphasizing the need for a system that warns them of impending hypoglycemia.

There have been many attempts to develop a non-invasive (NI)BG meter over the last few decades, but barriers still remain (Lin, 2017). Likewise, there has been attempts at developing a hypoglycemia alarm (Schechter *et al.*, 2012; Nguyen *et al.*, 2014; Ling *et al.*, 2016). A simple system based on sweat and temperature sensing has been available for many years, but does not perform at a level that may make it widely used (Clarke *et al.*, 1988). Most approaches so far involve simple sensor systems (i.e. only ECG or skin conductance), without the use of a detection model based on relevant physiology. Moreover, the previous studies have mainly assessed the detection of nocturnal hypoglycemia in people not classified as having IAH, which is less challenging than in those with IAH.

Physiological responses to hypoglycemia are particularly difficult to detect in people with IAH, in whom sympathoadrenal activation occur at a lower BG level than in those with normal hypoglycemia awareness (Hepburn *et al.*, 1991; Elvebakk *et al.*, 2018). Elvebakk 2018 found that global detection (using the same threshold for all cases) of hypoglycemia (down to 2.5 mmol/L) in IAH subjects was difficult based on the magnitudes of sudomotor and ECG (heart rate (HR) and QT-interval) responses. The present paper introduces a different approach for detection using a global probabilistic model which evens out individual dependencies and is able to discern episodes of hypoglycemia with better accuracy. In addition, non-invasive prediction of BG is used to further improve the accuracy, presenting the first results on a novel non-invasive multisensory system for detection of hypoglycemia.

The idea for the multisensory system is shown in figure 1. A fall in BG triggers an activation of the sympathetic nervous system, leading to a sudomotor response in innervated dermatomes, increased sympathetic output to the heart and excretion of adrenaline into the bloodstream, consequently increasing the HR and QT-time. Little is known about the sudomotor response to hypoglycemia, in particular which dermatomes of the body that are involved and the differences between individuals, especially between subjects with varying degrees of IAH. Tronstad *et al.* (Tronstad *et al.*, 2017) showed that amplification of synchronous changes in sudomotor activity (SA) measured at different skin sites (dermatomes) and HR was useful in detecting sympathoadrenal discharge. In IAH sympathoadrenal responses are attenuated (Hepburn *et al.*, 1991) and consequently more difficult to identify (Elvebakk *et al.*, 2018). Thus, new tailored algorithms and adding more information (through sensors) may improve the ability to detect hypoglycemia in this group. One largely independent

1
2
3 source of information is skin surface sensors for non-invasive prediction of BG (NIBG). Research and
4 development in NIBG has been going on for more than four decades, but the performance still
5 suffers from poor accuracy, physiological time lag and calibration issues (Lin, 2017). Nevertheless,
6 some indication of the BG level (i.e. high or low) and the BG trend (i.e. falling/rising) would provide
7 useful information, and seems possible to obtain using wearable non-invasive sensors (Caduff *et al.*,
8 2015). Being among the most tried and tested modalities with promising results in this regard is the
9 combination of optical and passive electrical tissue properties measured through the skin. For this
10 application, near-infrared (NIR) and bioimpedance spectroscopy have been selected as candidates
11 for the purpose of increasing the specificity of hypoglycemia detection by reducing the probability for
12 hypoglycemia when the predicted glucose level is too high or lacks a preceding negative trend. In
13 Tronstad *et al.* (Tronstad *et al.*, 2018), the combination of NIR and bioimpedance was assessed for
14 the non-invasive prediction of BG trends during hypoglycemia. The performance in predicting the BG
15 level was inaccurate with an unreliable threshold-based detection of hypoglycemia, but the trend
16 predictions were mostly able to reflect the fall in glucose toward hypoglycemia. Many factors not
17 related to hypoglycemia may interfere with the sensor measurements, mostly leading to false
18 positive signals by e.g. sympathoadrenal activation through exercise. Some of these confounders are
19 to some extent possible to measure and may provide information which can be used in the algorithm
20 to consider the likelihood of a detected physiological response being spurious. Such sensors include
21 an accelerometer for classification of activity level, one or more skin temperature sensors (for
22 correction of temperature effects in NIBG and contribution in classification of activity levels) and a
23 gyroscope for differentiation between lying and upright positions (different autonomic tone). The
24 accelerometer and skin temperature sensors may also provide information related to hypoglycemia
25 by detection of trembling (Muhlhauser *et al.*, 1991) and skin temperature changes when adrenaline
26 levels are high (Maggs *et al.*, 1994).
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Conceptual illustration of the idea for non-invasive detection of hypoglycemia using a wearable multisensory system. Non-invasive sensors are shown in yellow boxes, each measuring properties which are likely to contribute with relevant information for identifying a hypoglycemic episode. All sensors except the sensors addressing confounders are assessed in the current study, using data from a controlled laboratory environment. (Pictures by Servier medical art (<https://smart.servier.com>) licensed under CC BY 3.0).

The aim of this study was to develop a model for identification of physiological responses to hypoglycemia in people with T1D and IAH, and to assess the potential for improved non-invasive detection of hypoglycemia in these subjects by including the model in a wearable multisensory system. In this study, we consider all sensor data and knowledge acquired from a glucose clamp study in 20 participants with IAH. Sudomotor activity was recorded at four different skin sites, ECG was measured for HR and QT time, and NIR and bioimpedance spectra were acquired every five minutes, at the same time as blood was drawn for reference glucose measurement. The sensors for identifying confounders (as shown in figure 1) were not used in this study as the subjects were supine in a controlled laboratory environment, but they will be added to future wearable sensor systems and scrutinized in studies focused on detection of spontaneously occurring hypoglycemia.

Methods

Participants and glucose clamps

All sensor and BG data come from the same study of randomized single-blinded euglycemic and hypoglycemic glucose clamps in 20 participants with T1D and IAH, presented in a previous paper (Elvebakk *et al.*, 2018). Briefly, 20 subjects were recruited at Oslo University Hospital, The Norwegian Diabetics Centre and through an article in the Norwegian diabetes journal for patients. Inclusion criteria were age 18-60 years, T1D and IAH (defined by Clarke and/or Gold score (Clarke *et al.*, 1995; Gold *et al.*, 1994)). People with known heart, lung or kidney disease, ECG pathology, other serious medical conditions or the use of medication that could influence any measurements were excluded from the study.

Mean age was 41.1 (+/-10.9), mean BMI 25.1 (+/-2.8), mean duration of T1D 23.0 (+/-13.8) years and mean HbA1c 46.4 (+/-8.2) mmol/mol. Twelve of the subjects were women.

Signed informed consent was obtained from all participants, and the study was approved by the regional ethics committee in Norway (REK 2013/813). The sensor equipment setup was evaluated for electrical safety and approved by the appointed committee at Oslo University Hospital.

Each subject participated in two experimental sessions, one hypoglycemic and one euglycemic clamp, separated by at least two weeks. The subjects did not know which type of clamp that would be performed, and the order was randomized so that half of the subjects underwent hypoglycemic clamp first.

Participants were instructed to be extra careful to avoid hypoglycemic episodes 48 hours before each session and were hospitalized the night before clamps to have their BG stabilized with insulin/glucose infusion.

We used a hyperinsulinemic clamp technique with a constant rate insulin infusion of 1.5 mU/kg/min, and BG was regulated with a variable glucose infusion (Elvebakk *et al.*, 2018).

During hypoglycemic clamp, BG was lowered at a steady pace to 2.5 mmol/L and stabilized at this level for 15 minutes before being restored to normal levels. During euglycemic clamp, target BG was 5.3 mmol/L. BG was measured every 5 minutes (YSI 2300 STAT Plus glucose analyzer, YSI Life Sciences, Ohio, United States).

Sudomotor activity

Sudomotor activity was measured by the skin AC conductance method using a Sudologger (BioGauge AS, Oslo, Norway) device having four channels for simultaneous recording at different skin sites. Sensor electrodes of the type 1050NSPM (Covidien) were attached to the measuring sites of the hypothenar eminence of the left hand, the forehead, the abdomen (2 cm up and 2 cm to the right of the umbilicus at the T9 dermatome), and at the palmar wrist of the left arm. Skin AC conductance density (SC) in all channels was recorded four times per second. In order to reflect the activation of the sympathetic nervous system in favor of the interindividual passive electrical properties of the skin, the SC time-series were parameterized into the frequency of skin conductance responses (FSR) as in Tronstad *et al.* 2017 (Tronstad *et al.*, 2017). Briefly, FSR was calculated by using a five minute moving window, and counting the number of peaks (representing skin conductance responses to sudomotor activity) in the SC time-series within this window, giving a continuous indicator of the average sympathetic nervous system outflow to the different dermatomes where the sensor electrodes were placed. With respect to analysis of detection performance, the FSR time-series were shifted 2.5 minutes back in time so that no yet unknown data points were used in the analysis. Some non-physiologic spike artefacts were present in few recordings but were removed with a custom-

1
2
3 made spike-removal filter (interpolation between too sharp SC waves). Although the skin AC
4 conductance was measured at the hypothenar eminence of the palm, this sensor was not included in
5 the analysis of hypoglycemia detection, as the electrodermal activity at this site is very influenced by
6 emotional responses and the location is very impractical for a wearable sensor system.
7

8 ECG recording for heart rate and QT-interval

9 ECG was measured continuously using a Siemens SC9000XL ECG monitor and three Ambu Q00A
10 electrodes in the lead II configuration (which has been suggested as an acceptable substitute for the
11 mean QT-interval from a 12-lead recording (Davey, 2000)). The raw ECG signal was acquired by
12 sampling the analog output of the monitor by a DAQ-card (NI USB 6009 data acquisition device
13 National Instruments, Austin, Tx, USA) connected to a laptop running a custom made LabVIEW
14 (National Instruments, Austin, Tx, USA) application with a sampling rate of 300 Hz.
15

16 The raw ECG signals were initially processed by removing any signal parts having a voltage absolute
17 value larger than 1V (due to artefacts) and then low pass-filtering using a 3rd order Butterworth filter
18 with a 0.25 Nyquist rate (37.5 Hz corner frequency). The R peaks of the signal were then identified
19 using the Pan-Tompkins algorithm (Pan and Tompkins, 1985), and the time-distance between the
20 neighboring R peaks (the RR-time) was used for the calculation of the HR. Any RR-time lower than
21 500 ms or higher than 1500 ms was excluded due to most likely being an artefact. A heart-rate (HR)
22 time-series was then calculated from the reciprocal of the RR time in seconds and was finally filtered
23 by taking the median within a moving window of 5 minutes.
24

25 For calculation of the QT-interval, the bottom of the Q-wave (Q-point) and the end of the T-wave (T-
26 point) were located from the ECG signal using a previously published method (Laguna *et al.*, 1990).
27 The QT-interval was then calculated for each heartbeat by the difference between the T-point and
28 the Q-point of the same heartbeat. In order to minimize the influence of the HR variation on the QT-
29 interval, a correction by the Bazett formula (dividing the QT-interval by the square root of the RR-
30 interval in ms) was applied in order to predict the QT-interval at a reference HR of 60 beats per
31 minute (QTc). The Bazett formula was selected in favor of other proposed corrections based on
32 earlier work (Christensen *et al.*, 2010) which found that this formula was most suitable for observing
33 hypoglycemia-induced changes in the QT-interval. The HR-corrected QT-interval time-series were
34 also median filtered using a moving window of 5 minutes. The ECG recording was influenced by some
35 artefacts most likely due to muscle activity, but this influence on HR and QTc was diminished by the
36 median filtering. Similar to the FSR time-series, the HR and QTc time-series were also shifted 2.5
37 minutes back in time so that no unknown recordings at any time were used in the analysis of
38 hypoglycemia detection.
39

40 Skin temperature

41 Skin temperature was measured using a Siemens Drager 5204669 temperature probe taped to the
42 upper arm, not covered by clothing. The temperature value was acquired by the ECG monitor
43 (Siemens SC9000XL) connected to the probe and was recorded every 5 minutes at the same time as
44 BG measurement.
45

46 NIR and bioimpedance

47 NIR and bioimpedance spectroscopy was measured together with the physiological parameters of
48 FSR, HR and QTc for the purpose of increasing the specificity of hypoglycemia. NIR absorbance in the
49 880-2200 nm range was measured using a Spektron® (Prediktor AS) together with a 6.5 watt
50 tungsten light source (Ocean Optics Inc., Florida, USA) and a custom-made probe attached to the
51 upper arm. The custom-made probe had 6 illumination optical fibers surrounding a central pickup
52 fiber with a 0.2 mm distance between pickup and illumination fibers. Bioimpedance was measured in
53
54
55
56
57
58
59
60

the MHz range (1-200 MHz) using a VIA Echo 2500 vector impedance analyzer (AEA Technology, USA) using a 2-electrode configuration with electrodes (Ambu Q00-A) attached at the palmar side of the underarm. During the clamp, NIR and bioimpedance spectra were recorded every five minutes, at the same time as the BG measurement and skin temperature recording. These measurements were used to develop a global model for prediction of BG based on combining NIR, bioimpedance and skin temperature. An artificial neural network regression approach was used to train, validate and test the model and its performance in prediction of BG levels and trends, and is described in its completeness in Tronstad et al. (Tronstad *et al.*, 2019). The predicted BG time-series for each experiment based on the developed model was used in this study for the purpose of improving the specificity of hypoglycemia detection by combining the predicted BG levels and trends with the measured physiological responses.

Probabilistic model for detection of hypoglycemia

Based on the findings by Elvebakk et al (Elvebakk *et al.*, 2018) and further inspection of the data with respect to temporal properties of the sensors, the model presented in figure 2 was developed. The function of the model is to use a short history of sensor measurements to detect significant within-subject changes, and to combine the relevant changes from different sensors in a probabilistic network tuned to provide optimal sensitivity and specificity for detecting hypoglycemia.

For each sensor, a moving window of 30 minutes of measurement history was used to determine the probability that a significant change is occurring. The last measurement $m(i)$ in this window is compared to the mean value within the window, calculating the difference and standardized difference as:

$$diff(i) = m(i) - mean(m(window)) \quad (1)$$

$$std.diff(i) = \frac{m(i) - mean(m(window))}{std(m(window))} \quad (2)$$

These measures are then converted to a number between 0 and 1 by a sigmoid function where the output p represents the probability of change:

$$p(x) = \frac{1}{1 + e^{k(x-x_0)}} \quad (3)$$

Where x is the measure (diff or std.diff) and x_0 is the level of x at which $p(x)$ becomes 0.5, i.e. a 50% probability that the change has occurred, and k is the sharpness or sensitivity to changes around x_0 . In order to ensure that the change is not only statistically sufficient, but also sufficiently large in magnitude of the respective sensor, the probabilities of the difference (p_{diff}) and the standardized difference ($p_{std.diff}$) were multiplied (equivalent to a logical AND-gate) for each sensor, expressed as:

$$p_{sensor} = p_{diff} \cdot p_{std.diff} \quad (4)$$

The probabilities of reactions in the sudomotor activity sensors ($p_{forehead}$, $p_{abdomen}$ and p_{wrist}) were combined into a total probability of hypoglycemia-related sudomotor activity reaction (p_{FSR}) by finding the maximum pairwise product:

$$p_{FSR}(i) = \max(p_{Forehead}(i) \cdot p_{Abdomen}(i), p_{Forehead}(i) \cdot p_{Wrist}(i), p_{Abdomen}(i) \cdot p_{Wrist}(i)) \quad (5)$$

For the heart rate, the probability of change was also determined by (1), (2) and (3) and the product of p_{diff} and $p_{std.diff}$, representing the probability of a relevant increase in HR. This probability was then fed through a convolution filter (right half of a Gaussian with a sigma of 7 minutes) in order to smooth the response curves and keep p_{HR} elevated for a few minutes after a significant increase.

$P_{FSR\&HR}$ represents the probability of a sympathetic reaction that is due to hypoglycemia based on combining reactions in sudomotor activity (p_{FSR}) with heart rate in a way that increases the probability if there is a simultaneous heart rate reaction, but goes to zero if there is no sudomotor reaction, regardless of the p_{HR} value (as just standing up will give an increase in HR):

$$p_{FSR\&HR} = p_{FSR} \cdot (1 + k \cdot p_{HR}) \quad (6)$$

,where any $p_{FSR\&HR} > 1$ was set to 1. The probability of QT change associated with hypoglycemia was modeled in the same way using (1) to (4), also smoothed by convolution in the same way as p_{HR} . P_{QT} was combined with $p_{FSR\&HR}$ by the following relation, where negative $p_{FSR\&HR\&QT}$ values were set to zero:

$$p_{FSR\&HR\&QT} = p_{FSR\&HR} + P_{QT} - 1 \quad (7)$$

The last step of the model is using the NIBG predictions to filter out responses where the BG is likely to be either too high or lacking a negative foregoing trend. Probabilities of levels (p_{level}) and trends (p_{trend}) in BG associated with hypoglycemia were obtained by sigmoid activation functions as in (3). Due to a low precision of NIBG, the threshold level (x_0 in (3)) was set to 7.5 mmol/L. The trend was calculated from the slope of a linear regression against time within a 30 minutes window prior to the current measurement, and used to calculate the probability of a relevant trend based on (3) with x_0 set to -1 mmol/L/h. P_{NIBG} was calculated based on p_{level} and p_{trend} as:

$$p_{NIBG} = p_{level} - (1 - p_{trend}) / 2 \quad (8)$$

This implies that p_{NIBG} is reduced by 0.5 if the trend criterion is not met, and any negative p_{NIBG} is set to zero.

Finally, the probability of physiological responses due to hypoglycemia was modeled by:

$$p_{HYPO} = p_{FSR\&HR\&QT} \cdot p_{NIBG} \quad (9)$$

In this way, p_{HYPO} was allowed to remain high unless NIBG indicated too high BG or a lack of a preceding downward glucose trend.

The k value in (3) was set to 1 for all sensors, the k value in (6) was set to 0.5, and the x_0 values for calculating $p_{std.diff}$ for all sensors were also set to 1 (one standard deviation change from the mean gives a $p_{std.diff}$ of 0.5). For p_{diff} , the x_0 value was set to 2 for all sudomotor activity sensors and the QT interval, and 3 for the heart rate.

All signal processing and model development were done in Matlab R2018a (Mathworks Inc).




Figure 2. The structure of the probabilistic model used for detection of hypoglycemia based on the input from noninvasive sensors.

Performance assessment

Based on the probabilistic model and with all sensor recordings from each experiment, P_{HYP0} was calculated for each time-point from 30 minutes after the beginning of the experiment (due to the history window size) to the end of the recording, corresponding to the BG reference measurements. P_{HYP0} was then compared to the BG reference measurements, where the intervals having a reference BG below 4.0 mmol/L were defined as true hypoglycemic intervals. A true positive was counted for at least one P_{HYP0} above the detection threshold within this interval, else a false negative was counted. Within each of five euglycemic intervals (before and after the hypoglycemic interval of the hypoglycemic clamp, and the three intervals of the euglycemic clamp corresponding in time to the hypoglycemic intervals), a true negative was counted when there was no P_{HYP0} values above the detection threshold, and a false positive otherwise. Only unique P_{HYP0} responses were counted in the euglycemic intervals, i.e. not the tail of a response peaking within the hypoglycemic interval.

Sensitivity (same as recall), specificity, precision, F1-score, area under the ROC curve and the median and interquartiles of the detection time (in minutes relative to glucose nadir) was calculated as performance metrics, with the F1-score used as the metric for overall detection accuracy. These metrics were also calculated for different reduced combinations of sensors for comparison, where the same model was used, only with nodes removed from the model structure (see figure 2). When combining only two sudomotor activity sensors, the following formula was used for p_{FSR} :

$$p_{FSR} = 1 - (1 - p_{FSR,Sensor1}) (1 - p_{FSR,Sensor2}) \quad (10)$$

Results

The application of the model on sensor data during hypoglycemia is demonstrated in figure 3. As shown in the b) plot, the sudomotor activity increases around 20 minutes before glucose nadir (the point of lowest BG during the hypoglycemic clamps), both at the forehead and wrist sites. Even though the magnitude increases from nadir and onwards, it is the wave of responses around -10 minutes that is most synchronous (between skin sites) and gives the largest probability value of relevant sudomotor activation, as shown in the d) plot. Shown in e) and f), the probabilities of relevant increases both in HR and QTc are also maxed around this time. Together, these probabilities satisfy the criteria for a non-zero p_{HYP0} around nadir-10 minutes, which is not attenuated much by the NIBG time-series, having both a low enough predicted glucose level and preceding trend to keep p_{NIBG} high around this time, as shown in g). The result is a distinct p_{HYP0} response around nadir -10 minutes as shown in h).




Figure 3. Example of the model applied on sensor data from one hypoglycemic clamp experiment showing the different steps in determining the probability of hypoglycemia (p_{HYPO}) using the combination of time-series representing sudomotor activity (b-d), HR (e), QT time (f) and non-invasive prediction of BG (g). Probabilities before -80 minutes before glucose nadir are not available due to the window length required.

The model was able to discern reactions during episodes of hypoglycemia based on the sensor inputs with a high accuracy (F1 score of 88%). As shown in figure 4, p_{HYPO} responses were prominent around the time of glucose nadir in the hypoglycemic clamp (upper plot). During the euglycemic clamps, there were two large p_{HYPO} responses and a few smaller, regarded as false positives depending on the detection threshold level.




Figure 4. The probability of a physiological response due to hypoglycemia based on the combination of all sensors, P_{HYPO} , plotted vs time relative to glucose nadir for all hypoglycemic (above) and euglycemic (below) clamps plotted. P_{HYPO} is represented in black lines together with the mean plasma glucose over all experiments (red dots) on the right y-axis.




Figure 5. Performance of detection vs threshold of detection. The black line shows the threshold value with the highest F1-score (88%) at $P_{HYP0}=0.10$.

The performance of hypoglycemia detection versus detection threshold is shown in figure 5. The maximum accuracy (based on the F1-score) was with a P_{HYP0} threshold at 0.10, with an 88% accuracy having one false negative and four false positives. Further performance metrics at the optimal detection threshold is shown in table 1, also for other sensor combinations for comparison. Excluding NIBG reduced the accuracy to 86% (due to lower precision). Interestingly, excluding the HR sensor input did not change the detection performance (except for a bit lower sensitivity and higher precision). A large fall in accuracy was found when the QT time was excluded, hampering both the sensitivity and precision. Using only the abdomen and wrist SA sensors together with both ECG sensors provided an accuracy of 81%. Only using SA data from the wrist site together with both ECG sensors reduced the accuracy to 78%, mainly due to low sensitivity. The combination of only wrist SA together with HR had an accuracy of 55%, with very low precision.

Table 1. Detection performance parameters for the model using all sensors and other selected sensor combinations using the same model. FSR = Frequency of Sudomotor Responses, F=Forehead, A=Abdomen, W=Wrist, HR=Heart Rate, QTc=HR-corrected QT-interval, NIBG = Non-Invasive Blood Glucose, IQR = Inter-Quartile Range. The detection time is calculated as the median and inter-quartiles of the time when an alarm would have triggered in minutes relative to glucose nadir.

Sensors	Max F1 score [%]	Sensitivity [%]	Specificity [%]	Precision [%]	AU _{ROC} [0-1]	Detection time median (IQR) [min]
FSR(F+A+W)+ECG(HR+QTc)+NIBG	88	95	96	83	0.97	-2.2 (-11.6, 4.2)
FSR (F+A+W) + ECG (HR + QTc)	86	95	95	79	0.96	-2.2 (-11.6, 4.2)
FSR(F+A+W)+ECG(HR)+NIBG	63	65	92	62	0.87	-10.8 (-27.6, -1.0)
FSR(F+A+W)+ECG(QTc)+NIBG	86	90	96	82	0.97	-3.0 (-11.8, 3.2)
FSR (A+W)+ECG(HR+QTc)+NIBG	83	75	99	94	0.94	-2.2 (-9.2, 4.1)
FSR (A+W) + ECG (HR + QTc)	81	75	98	88	0.94	-2.0 (-10.8, 6.3)
FSR (W) + ECG (HR + QTc)	78	70	98	88	0.91	-5.3 (-11.8, 4.8)
FSR (W) + ECG (HR)	55	75	80	43	0.80	-13.5 (-25.9, 1.3)
ECG (HR+QTc) + NIBG	58	45	98	82	0.79	-0.83 (-6.2, 2.2)

In Elvebakk et al. (Elvebakk *et al.*, 2018), it was found that five of the 20 subjects could identify hypoglycemia during the clamp experiments. Reducing the sample to the remaining 15 subjects gave a slightly lower performance (F1 score) when using all sensors (87%), a reduction to 77% for the two combinations using abdomen and wrist sweating and 74% for wrist sweating, HR and QTc. A drop in performance was also given for the combination of only FSR wrist and HR combination (51%), for the combination using all sensors without QTc (59% F1 score) and for the ECG + NIBG combination (42%).

Discussion

Summary of findings

We have shown that a probabilistic multiparameter model can identify physiological responses during hypoglycemia with a high accuracy using non-invasive sensors, even in people with IAH. Using three SA sensors together with ECG and NIBG, this accuracy was 88%. For a more practical sensor combination with respect to wearability (SA sensors from wrist and abdomen combined with ECG), an accuracy of 81% was obtained.

Physiological interpretation

Based on earlier research we were prepared to find that not all subjects would have measurable reactions to a BG of 2.5 mmol/L (Hepburn *et al.*, 1991). Detecting 19/20 (95% sensitivity) hypoglycemias in people with IAH would be very attractive if proven to work that well in realistic settings. Since we rely much on a sympathetic reaction, any sympathetic reaction could potentially trigger an alarm. However, none of the false alarms were accompanied by increases in adrenaline or typical symptoms of a sympathetic reaction. The same can be said for some of the alarms during hypoglycemia, since many of the subjects had uncertain reactions to hypoglycemia, yet we could still detect small (possibly sympathetic) sensor reactions in all but one participant. It is therefore difficult to conclude whether our model has detected actual sympathetic reactions during euglycemia (due to other unknown triggers), or random triggering events.

Clinical significance

One out of 20 hypoglycemic episodes was not detected by our model. Since the sympathetic reaction to hypoglycemia is triggered at a lower BG level in IAH subjects than in people with normal hypoglycemia awareness, this is not surprising. But more importantly, only five out of 20 subjects recognized hypoglycemia during the hypoglycemic clamps. Subtracting one undetected case leaves 14 subjects that had detectable physiological reactions without recognizing these reactions. This may

1
2
3 imply that even in people with complete hypoglycemia unawareness our device may detect
4 hypoglycemia in time for them to self-treat. However, since one hypoglycemic episode was
5 undetected, it may seem that not only the sympathetic reaction is shifted to a lower BG level in these
6 people, but also the sensors' ability to detect it. This could mean that in some people, it may be
7 impossible to detect hypoglycemia in due time based on these sensors.
8

9
10 Looking at figure 4, we observe that many of the calculated responses to hypoglycemia appear
11 around 10 minutes after glucose nadir. Much, if not all of this can be explained by data processing. A
12 delay of about 10 minutes is not ideal, as BG can fall 0.5 mmol/L or more during that time period,
13 which might be crucial if the response should appear at around 2.0 mmol/L and the alarm alerts at
14 1.5 mmol/L. The model is tuned to achieve optimal sensitivity and precision, but further testing in a
15 real-world setting is needed to decide if other factors should be weighted more.
16

17
18 Today, the CGMs that are available for many people with T1D are minimally invasive, implying that
19 only a very thin and short plastic catheter penetrates the skin after being inserted via a small needle.
20 A small transmitter device sticks to the skin over the catheter. For many people with T1D such CGM
21 devices are very useful, but IAH continues to be a risk factor for severe hypoglycemia despite the use
22 of CGM (Lin *et al.*, 2019). Also, CGMs imply a considerable cost, and reimbursement by the health
23 care system is variable. For a non-invasive alarm system to be relevant, it would have to be easy to
24 use (CGMs require a minimum of technical interest/knowledge), be non-obtrusive, relatively cheap,
25 and reliable. Modern CGMs are convenient and inobtrusive for most users, while some instantiations
26 of the proposed system would be obtrusive and would benefit from new solutions in sensor design.
27 An advantage of the proposed system is that realizations of the device would not require expensive
28 components, and the use would not require regular replacement of any expensive part, in addition to
29 being non-invasive.
30
31

32 Sensor design

33
34 The presented combinations of sensors may seem obtrusive for a wearable system, especially when
35 using all SA sensors together with ECG and NIBG (NIR and bioimpedance). However, recent and
36 future advances in sensor miniaturization and sensor network architecture will likely reduce the
37 obtrusiveness of a complex multisensory system significantly, combining wireless sensor patches
38 communicating in a body area network. Skin conductance (for SA) can be measured by stamp-size
39 skin patches, as demonstrated by Yoon *et al.* 2016. Miniaturized and wireless ECG patch sensors are
40 already available, such as the SEEQ MCT by Medtronic and the ZIO® XT Patch by iRhythm. With
41 respect to NIBG sensors, the technological development also facilitates wearable solutions for NIR
42 and bioimpedance (the sensors used in this study). Bioimpedance has the advantage that being an
43 electrical measurement, no other transducer than a suitable electrode is needed, allowing easy
44 sensor miniaturization. ASIC solutions for bioimpedance measurement fabricated in CMOS are
45 emerging (Rodriguez *et al.*, 2016; Zamani *et al.*, 2018; Xu *et al.*, 2015) and wearable patch solutions
46 have been found suitable for bioimpedance sensing (Rossi *et al.*, 2017). Miniature NIR spectrometers
47 in CMOS are also emerging (Hong and Sengupta, 2017), which will be beneficial for application in
48 non-invasive glucose monitoring (Yadav *et al.*, 2015). An integrated circuit for measurement and
49 processing of both NIR and bioimpedance has been proposed (Song *et al.*, 2015), and a wristwatch
50 device with both sensors integrated has already been developed (Carlsen *et al.*, 2016). Advances in
51 research on stretchable materials leads to development of new flexible wearable sensor platforms
52 which may be useful in this application (Kenry *et al.*, 2016). In addition, the developments in the
53 Internet of Things (IoT) will likely pave the way for new solutions in sensor fusion and predictive
54 analytics (Li *et al.*, 2014).
55
56
57
58
59

60 Degree of IAH and personalization

1
2
3 The model used was global (equally applied to the data from all subjects and experiments in the
4 study), and the detection threshold was the same for all experiments. The detection performance
5 could possibly be improved by personalization with respect to the degree of IAH (i.e. lowering of the
6 detection threshold due to anticipated weaker physiological responses), and a simpler model (with
7 fewer sensors) may provide sufficient detection performance for people with IAH that still have a
8 strong sympathetic reaction (Elvebakk *et al.*, 2018). Studying the effect of personalization would
9 require longer recordings with several hypoglycemic episodes in order to test the reproducibility of
10 individual adjustments.
11
12

13 Comparison to other works

14 In our previous study (Elvebakk *et al.*, 2018), we demonstrated that simple processing (as in
15 (Tronstad *et al.*, 2017)) of SA and ECG sensor data and a global threshold could provide detection of
16 hypoglycemia in people with diabetes with normal/adequate hormonal reactions to hypoglycemia
17 (100% accuracy in five subjects), but had a poor detection performance in people with IAH due to
18 interindividual differences in the magnitude of symptomatic responses. The probabilistic approach
19 presented here leveled out this interindividual variation, mainly by the non-linear transformation in
20 the sigmoid functions and also increasing the sensitivity to weaker responses by the network
21 structure of the model, thereby improving the identification of hypoglycemic responses significantly.
22
23
24

25 To the authors' knowledge, only one previous study has been published on non-invasive detection of
26 hypoglycemia in people with IAH, and several studies have assessed non-invasive hypoglycemia
27 detection using different sensor systems in people with T1D, but with no consideration of
28 hypoglycemia awareness (see below).
29

30 Sejling *et al.* (Sejling *et al.*, 2015) showed that hypoglycemia could be detected with EEG, and that
31 there was no difference in the EEG signals between subjects with T1D with and without IAH when in
32 the hypoglycemic range. A product called Hypo-Safe is under development, but as of now not
33 commercially available.
34
35

36 Schechter *et al.* (Schechter *et al.*, 2012) used a sensor system of HR, perspiration (unprocessed skin
37 conductance at the fingertips), skin temperature and tremor (by accelerometer) measurements and
38 obtained a sensitivity of 100% and a specificity of 85.7% in detecting nocturnal hypoglycemia in a
39 pilot study in ten adolescents with type 1 diabetes. Clewett *et al.* demonstrated feasibility of non-
40 invasive EEG-based hypoglycemia warning in a single case study (Clewett *et al.*, 2016).
41
42

43 Recently, machine-learning approaches for hypoglycemia detection have also been attempted
44 (Nguyen *et al.*, 2014, Huang *et al.*, 2011, Ling *et al.*, 2016, Marling *et al.*, 2016) based on similar
45 sensors such as ECG, skin conductance and temperature, but are difficult to compare with the
46 present study due to differences in population, study design and performance measures. It seems
47 that too little data from too few studies have so far been gathered in order to evaluate the potential
48 for non-invasive detection of hypoglycemia using machine-learning methods.
49

50 Previous studies involving skin conductance (or other names thereof, such as galvanic skin reflex or
51 electrodermal activity) have used the raw measurement without any parameterization. In the
52 present study, signal processing of this measurement was employed in order to extract the FSR
53 (frequency of sudomotor responses), reducing the between-subjects variation due to skin properties
54 and more closely representing the state of sympathoadrenal activation (Tronstad *et al.*, 2017).
55
56

57 Limitations of the present study

58 Although the dataset used in this study is large compared to other studies (40 glucose clamp
59 experiments in 20 subjects), data scarcity is also considered a limit of this study. Especially in the IAH
60

1
2
3 population, large interindividual differences in hormonal reactions to hypoglycemia and the
4 associated physiological responses necessitate a large sample. Although machine-learning was not
5 employed in the present study, some manual tuning of several parameters (i.e. x_0 in (3)) was done in
6 order to translate relevant changes in sensor measurements into reasonable probabilities for their
7 respective physiological parameter, implying some risk of overfitting. In addition, the structure of the
8 model (figure 2) was developed by a combination of logical reasoning and optimization of global
9 detection accuracy on this dataset. Hence, this is an introduction of a model for identification of
10 physiological responses due to hypoglycemia, an assessment of its potential for detecting
11 hypoglycemia, but not a validation of it.
12
13

14
15 A strength of this study, however, is the participant-blinded randomized control clamp that provided
16 measurements during similar conditions but at euglycemic levels, greatly reducing the chance of
17 overfitting and spurious relationships. It is also not possible to know whether all detected responses
18 within the hypoglycemic window are causally related to BG decrease, especially those who peak
19 more than 10 minutes after glucose nadir (see figure 4). Given the latency due to signal processing, a
20 possible latency in the physiological response to hypoglycemia and the lack of time-corresponding
21 responses in the euglycemic clamp, we believe that they are most likely a consequence of
22 hypoglycemia. Ideally, the model would be tuned further on a larger sample from the same
23 population with data from several hypoglycemic episodes per subject, and then validated on a new
24 sample from the same population. The measurements in this study were done during glucose clamp
25 in a controlled laboratory environment in order to study the physiological responses to hypoglycemia
26 as specifically as possible. Using a wearable device with the same sensors as described in figure 1, the
27 detection performance can be evaluated in a more realistic setting during daily activities and during
28 sleep. Further studies should also include an assessment of the potential for reductions in
29 uncorrected hypoglycemic episodes and a comparison with recent CGM technology.
30
31
32

33 Conclusion

34 In conclusion, we have presented a novel model for identification of non-invasively measurable
35 physiological responses related to hypoglycemia, showing potential for the detection of moderate
36 hypoglycemia in people with T1D and IAH using a wearable sensor system.
37
38

39 Acknowledgements

40 This work was supported by funding from the South-Eastern Norway Regional Health Authority and
41 the Norwegian Diabetes Association.
42
43

44 The Authors would like to thank all study participants and nurses involved in the study, in particular
45 Åse Halsne, Gørild Vinje, Karin Eide and Gro Boezelijn, nurses at the Diabetes Laboratory, Oslo
46 University Hospital, for assistance during the clamping experiments.
47
48

49 References

50
51 Agesen R M, Kristensen P L, Beck-Nielsen H, Norgaard K, Perrild H, Jensen T, Parving H H,
52 Thorsteinsson B, Tarnow L and Pedersen-Bjergaard U 2018 Effect of Insulin Analogs on
53 Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe
54 Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-
55 Monitoring of Blood Glucose-The HypoAna Trial *Diabetes technology & therapeutics* **20** 247-
56 56
57
58
59
60

- 1
2
3 Anderbro T, Amsberg S, Adamson U, Bolinder J, Lins P E, Wredling R, Moberg E, Lisspers J and
4 Johansson U B 2010 Fear of hypoglycaemia in adults with Type 1 diabetes *Diabet Med* **27**
5 1151-8
6
7 Caduff A, Zanon M, Mueller M, Zakharov P, Feldman Y, De Feo O, Donath M, Stahel W A and Talary M
8 S 2015 The Effect of a Global, Subject, and Device-Specific Model on a Noninvasive Glucose
9 Monitoring Multisensor System *J Diabetes Sci Technol* **9** 865-72
10
11 Carlsen S, Fougner A, Vegar Karstang T, Staal O and Christian Christiansen S 2016 Continuous Non-
12 Invasive Glucose Monitoring by Sensor Fusion of Near Infrared Light and Bioimpedance
13 Measurements: Results of a Proof of Concept Study *Conference on Advanced Technologies &*
14 *Treatments for Diabetes (ATTD) Milano, Italy*. DOI: 10.13140/RG.2.2.34384.10247
15
16 Christensen T F, Randlov J, Kristensen L E, Eldrup E, Hejlesen O K and Struijk J J 2010 QT
17 Measurement and Heart Rate Correction during Hypoglycemia: Is There a Bias? *Cardiol Res*
18 *Pract* **2010** 961290
19
20 Clarke W L, Carter W R, Moll M, Cox D J, Gonder-Frederick L A and Cryer P E 1988 Metabolic and
21 cutaneous events associated with hypoglycemia detected by sleep sentry *Diabetes Care* **11**
22 630-5
23
24 Clarke W L, Cox D J, Gonder-Frederick L A, Julian D, Schlundt D and Polonsky W 1995 Reduced
25 awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic
26 frequency and associated symptoms *Diabetes Care* **18** 517-22
27
28 Clewett C J, Langley P, Bateson A D, Asghar A and Wilkinson A J 2016 Non-invasive, home-based
29 electroencephalography hypoglycaemia warning system for personal monitoring using skin
30 surface electrodes: a single-case feasibility study. In: *Healthcare Technology Letters:*
31 *Institution of Engineering and Technology*) pp 2-5
32
33 Davey P P 2000 Which lead for Q-T interval measurements? *Cardiology* **94** 159-64
34
35 Elvebakk O, Tronstad C, Birkeland K I, Jenssen T G, Bjorgaas M R, Frosli K F, Godang K, Kalvoy H,
36 Martinsen O G and Gulseth H L 2018 Evaluation of Hypoglycaemia with Non-Invasive Sensors
37 in People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia *Sci Rep* **8** 14722
38
39 Gagnum V, Stene L C, Sandvik L, Fagerland M W, Njolstad P R, Joner G and Skriverhaug T 2015 All-
40 cause mortality in a nationwide cohort of childhood-onset diabetes in Norway 1973-2013
41 *Diabetologia* **58** 1779-86
42
43 Geddes J, Schopman J E, Zammitt N N and Frier B M 2008 Prevalence of impaired awareness of
44 hypoglycaemia in adults with Type 1 diabetes *Diabet Med* **25** 501-4
45
46 Gold A E, MacLeod K M and Frier B M 1994 Frequency of severe hypoglycemia in patients with type I
47 diabetes with impaired awareness of hypoglycemia *Diabetes Care* **17** 697-703
48
49 Graveling A J and Frier B M 2010 Impaired awareness of hypoglycaemia: a review *Diabetes &*
50 *metabolism* **36 Suppl 3** S64-74
51
52 Graveling A J, Noyes K J, Allerhand M H, Wright R J, Bath L E, Deary I J and Frier B M 2014 Prevalence
53 of impaired awareness of hypoglycemia and identification of predictive symptoms in children
54 and adolescents with type 1 diabetes *Pediatr Diabetes* **15** 206-13
55
56 Hepburn D A, Patrick A W, Brash H M, Thomson I and Frier B M 1991 Hypoglycaemia unawareness in
57 type 1 diabetes: a lower plasma glucose is required to stimulate sympatho-adrenal activation
58 *Diabet Med* **8** 934-45
59
60 Hong L and Sengupta K 2017 Fully Integrated Optical Spectrometer in Visible and Near-IR in CMOS
IEEE Trans Biomed Circuits Syst **11** 1176-91
Huang G-B, Hui Wang D and Lan Y 2011 *Extreme learning machines: a survey*. *Int J Mach Learn Cybern*
vol 2
Kenry, Yeo J C and Lim C T 2016 Emerging flexible and wearable physical sensing platforms for
healthcare and biomedical applications *Microsystems & Nanoengineering* **2** 16043
Laguna P, Thakor N V, Caminal P, Jane R, Yoon H R, Bayes de Luna A, Marti V and Guindo J 1990 New
algorithm for QT interval analysis in 24-hour Holter ECG: performance and applications *Med*
Biol Eng Comput **28** 67-73
Li S, Xu L D and Zhao S 2014 The internet of things: a survey *Information Systems Frontiers* **17** 16

- 1
2
3 Lin T 2017 *Non-Invasive Glucose Monitoring: A Review of Challenges and Recent Advances* vol 6
4 Lin Y K, Hung M, Sharma A, Chan O, Varner M W, Staskus G and Fisher S J 2019 Impaired awareness
5 of hypoglycemia continues to be a risk factor for severe hypoglycemia despite the use of
6 continuous glucose monitoring system in type 1 diabetes *Endocrine Practice* **25** 517-525.
7 Lind M, Svensson A M, Kosiborod M, Gudbjornsdottir S, Pivodic A, Wedel H, Dahlqvist S, Clements M
8 and Rosengren A 2014 Glycemic control and excess mortality in type 1 diabetes *N Engl J Med*
9 **371** 1972-82
10 Ling S H, San P P and Nguyen H T 2016 Non-invasive hypoglycemia monitoring system using extreme
11 learning machine for Type 1 diabetes *ISA transactions* **64** 440-6
12 Livingstone S J, Looker H C, Hothersall E J, Wild S H, Lindsay R S, Chalmers J, Cleland S, Leese G P,
13 McKnight J, Morris A D, Pearson D W, Peden N R, Petrie J R, Philip S, Sattar N, Sullivan F and
14 Colhoun H M 2012 Risk of cardiovascular disease and total mortality in adults with type 1
15 diabetes: Scottish registry linkage study *PLoS medicine* **9** e1001321
16 Maggs D G, Macdonald I A and Tattersall R B 1994 Thermoregulatory responses to hyperinsulinaemic
17 hypoglycaemia and euglycaemia in IDDM *Diabetologia* **37** 689-96
18 Marling C, Xia L, Bunescu R and Schwartz F L 2016 Machine Learning Experiments with Noninvasive
19 Sensors for Hypoglycemia Detection. In: *Proceedings of IJCAI 2016 Workshop on Knowledge*
20 *Discovery in Healthcare Data*, pp 1-6
21 Muhlhauser I, Heinemann L, Fritsche E, von Lennep K and Berger M 1991 Hypoglycemic symptoms
22 and frequency of severe hypoglycemia in patients treated with human and animal insulin
23 preparations *Diabetes Care* **14** 745-9
24 Nguyen L L, Su S and Nguyen H T 2014 Neural network approach for non-invasive detection of
25 hyperglycemia using electrocardiographic signals *Conference proceedings : ... Annual*
26 *International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE*
27 *Engineering in Medicine and Biology Society. Annual Conference* **2014** 4475-8
28 Olsen SE, Asvold BO, Frier BM, Aune SE, Hansen LI, Bjørgaas MR. 2014 Hypoglycaemia
29 symptoms and impaired awareness of hypoglycaemia in adults with Type 1 diabetes: the association
30 with diabetes duration. *Diabet Med* **31** 1210-7.
31 Pan J and Tompkins W J 1985 A real-time QRS detection algorithm *IEEE Trans Biomed Eng* **32** 230-6
32 Rodriguez S, Ollmar S, Waqar M and Rusu A 2016 A Batteryless Sensor ASIC for Implantable Bio-
33 Impedance Applications *IEEE Transactions on Biomedical Circuits and Systems* **10** 533-44
34 Rossi S, Mancarella C, Mocenni C and Torre L D 2017 Bioimpedance sensing in wearable systems:
35 From hardware integration to model development. In: *2017 IEEE 3rd International Forum on*
36 *Research and Technologies for Society and Industry (RTSI)*, pp 1-6
37 Schechter A, Eyal O, Zuckerman-Levin N, Amihai-Ben-Yaacov V, Weintrob N and Shehadeh N 2012 A
38 prototype of a new noninvasive device to detect nocturnal hypoglycemia in adolescents with
39 type 1 diabetes--a pilot study *Diabetes technology & therapeutics* **14** 683-9
40 Secret A M, Becker D J, Kelsey S F, LaPorte R E and Orchard T J 2010 All-cause mortality trends in a
41 large population-based cohort with long-standing childhood-onset type 1 diabetes: the
42 Allegheny County type 1 diabetes registry *Diabetes Care* **33** 2573-9
43 Secret A M, Becker D J, Kelsey S F, Laporte R E and Orchard T J 2011 Characterizing sudden death
44 and dead-in-bed syndrome in Type 1 diabetes: analysis from two childhood-onset Type 1
45 diabetes registries *Diabet Med* **28** 293-300
46 Sejling A S, Kjaer T W, Pedersen-Bjergaard U, Diemar S S, Frandsen C S, Hilsted L, Faber J, Holst J J,
47 Tarnow L, Nielsen M N, Remvig L S, Thorsteinsson B and Juhl C B 2015 Hypoglycemia-
48 associated changes in the electroencephalogram in patients with type 1 diabetes and normal
49 hypoglycemia awareness or unawareness *Diabetes* **64** 1760-9
50 Song K, Ha U, Park S, Bae J and Yoo H 2015 An Impedance and Multi-Wavelength Near-Infrared
51 Spectroscopy IC for Non-Invasive Blood Glucose Estimation *IEEE Journal of Solid-State Circuits*
52 **50** 1025-37
53 Tronstad C, Elvebakk O, Kalvoy H, Bjørgaas M R and Martinsen O G 2017 Detection of
54 sympathoadrenal discharge by parameterisation of skin conductance and ECG measurement
55
56
57
58
59
60

1
2
3 *Conference proceedings : ... Annual International Conference of the IEEE Engineering in*
4 *Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual*
5 *Conference* **2017** 3997-4000

6 Tronstad C, Elvebakk O, Staal O M, Kalvøy H, Høgetveit J O, Jenssen T G, Birkeland K I and Martinsen
7 Ø G 2019 Non-invasive prediction of blood glucose trends during hypoglycemia *Analytica*
8 *Chimica Acta* **1052** 37-48

9
10 Xu J, Harpe P, Pettine J, Hoof C V and Yazicioglu R F 2015 A low power configurable bio-impedance
11 spectroscopy (BIS) ASIC with simultaneous ECG and respiration recording functionality. In:
12 *ESSCIRC Conference 2015 - 41st European Solid-State Circuits Conference (ESSCIRC)*, pp 396-9

13 Yadav J, Rani A, Singh V and Murari B M 2015 Prospects and limitations of non-invasive blood glucose
14 monitoring using near-infrared spectroscopy *Biomedical Signal Processing and Control* **18**
15 214-27

16 Zamani M, Rezaeiyan Y, Shoaie O and Serdijn W A 2018 A 1.55 μ W Bio-Impedance Measurement
17 System for Implantable Cardiac Pacemakers in 0.18 μ m CMOS *IEEE Transactions on*
18 *Biomedical Circuits and Systems* **12** 211-21
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60